DNA damage signals induction of Fas ligand in tumor cells

Molecular Pharmacology

Volumn 55, Issue 2, 1999, Pages 216-222

  Mo, Yin Yuan ^a   Beck, William T ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FAS LIGAND; TENIPOSIDE;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA DAMAGE; HELA CELL; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; SIGNAL TRANSDUCTION;

EID: 0033054992     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.55.2.216     Document Type: Article

References (36)

1. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA and Struhl K (1989) Current Protocols in Molecular Biology, Wiley-Interscience, New York.
2. Beere HM, Chresta CM and Hickman JA (1996) Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells. Mol Pharmacol 49:842-851.
3. Brill SJ, DiNardo S, Voelkel-Meiman K and Sternglanz R (1987) Need for DNA topoisomerase activity as a swivel for DNA replication for transcription of ribosomal RNA. Nature (London) 326:414-416.
4. D'Arpa P, Machlin PS, Ratrie H III, Rothfield NF, Cleveland DW and Earnshaw WC (1988) cDNA cloning of human DNA topoisomerase I: Catalytic activity of a 67.7-kDa carboxyl-terminal fragment. Proc Natl Acad Sci USA 85:2543-2547.
5. Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ and Kaufmann SH (1997) Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood 90:935-943.
6. Fisher DE (1994) Apoptosis in cancer therapy: crossing the threshold. Cell 78:539-542.
7. Friesen C, Herr I, Krammer P and Debatin K-M (1996) Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2:574-577.
8. Fulda S, Sieverts H, Friesen C, Herr I and Debatin K-M (1997) The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 57:3823-3829.
9. Gutierrez-Steil C, Wrone-Smith T, Sun X, Krueger JG, Coven T and Nickoloff BJ (1998) Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-B-irradiated psoriatic plaques express Fas ligand (CD95L). J Clin Invest 101:33-39.
10. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontan A, Lienard D, Cerottini J-C and Tshopp J (1996) Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape. Science (Wash DC) 274:1363-1366.
11. Heck MM and Earnshaw W (1986) Topoisomerase II, a specific marker for cell proliferation. J Cell Biol 103:2569-2581.
12. Herr I, Wilhelm D, Böhler T, Angel P and Debatin KM (1997) Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J 16:6200-6208.
13. Holtz-Heppelmann C J, Algeciras A, Badley AD and Paya CV (1998) Transcriptional regulation of the human FasL promoter-enhancer region. J Biol Chem 273:4416-4423.
14. Jensen PB and Sehested M (1997) DNA topoisomerase II rescue by catalytic inhibitors. Biochem Pharmacol 54:755-759.
15. Jordan M, Schallhorn A and Wurm FM (1996) Transfecting mammalian cells: Optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res 24:596-601.
16. Ju S-T, Panka DJ, Cui H, Ettinger R, El-Khatib M, Sherr DH, Stanger BZ and Marshak-Rothstein A (1995) Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature (London) 373:444-448.
17. Kasibhatla S, Brunner T, Genestier L, Echverri F, Mahboubi A and Green DR (1998) DNA damaging agents induce expression of FasL ligand and subsequent apoptosis in T lymphocytes via the activation of NF-κB and AP-1. Mol Cell 1:543-551.
18. Keane MM, Ettenberg SA, Lowrey GA, Russell EK and Lipkowitz S (1996) Fas expression and function in normal and malignant breast cell lines. Cancer Res 56:4791-4798.
19. Kusumoto H, Rodgers QE, Boege F, Raimondi SC and Beck WT (1996) Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II. Cancer Res 56:2573-2583.
20. Latinis KM, Norian LA, Eliason SL and Koretzky GA (1997) Two NFAT transcription factor binding sites participate in the regulation of CD95 (Fas) ligand expression in activated human T cells. J Biol Chem 272:31427-31434.
21. Leverkus M, Yaar M and Gilchrest BA (1997) Fas/Fas Ligand interaction contributes to UV-induced apoptosis in human keratinocytes. Exp Cell Res 232:255-262.
22. Lowin B, Hahne M, Mattmann C and Tchopp J (1994) Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature (London) 370:650-652.
23. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351-375.
24. Nagata S and Golstein P (1995) The Fas death factor. Science (Wash DC) 267:1449-1456.
25. Nelson WG, Liu LF and Coffey DS (1986) Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells. Nature (London) 322:187-189.
26. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR. and Kratzke RA (1997) Human lung carcinomas express Fas ligand. Cancer Res 57:1007-1012.
27. Osheroff N, Corbett AH and Robinson MJ (1994) Mechanism of action of topoisomerase II-targeted antineoplastic drugs. Adv Pharmacol 29:B105-B126.
28. Rose D and Holm C (1993) Meiosis-specific arrest revealed in DNA topoisomerase II mutants. Mol Cell Biol 13:3445-3455.
29. Rouvier E, Luciani MF and Golstein P (1993) Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med 177:195-200.
30. Sehested M, Buhl P, Sorenson BS, Holm B, Friche E and Demant EJF (1993) Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etopside (VP-16). Biochem Pharmacol 46:389-393.
31. Sehested M and Jensen PB (1996) Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol 51:879-886.
32. Sekiguchi J and Shuman S (1997) Site-specific ribonuclease activity of eukaryotic DNA topoisomerase I. Mol Cell 1:89-97.
33. Shieh S-Y, Ikeda M, Taya Y and Prives C (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334.
34. Strand S, Hofmann WJ, Hug F, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer P and Gale PR (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: A mechanism of immune evasion? Nat Med 2:1361-1366.
35. Tsai-Pflugfelder M, Liu LF, Liu AA, Tewey KM, Whang-Peng J, Knutsen T, Huebner K, Croce CM and Wang JC (1988) Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci USA 85:7177-7181.
36. Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R and Greil R (1997) Drug-induced apoptosis is associated with enhanced Fas (APO-1/CD95) ligand expression but occurs independently of Fas (APO-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res 67:3331-3334.